MERZEE
Clinical safety rating
cautionComprehensive clinical and safety monograph for MERZEE (MERZEE).
MERZEE (benzphetamine) is a sympathomimetic amine that stimulates the release of norepinephrine and dopamine from nerve terminals in the hypothalamus, leading to appetite suppression and increased energy expenditure.
| Metabolism | Primarily hepatic via N-demethylation and other oxidative pathways; metabolites include amphetamine and methamphetamine. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; biliary/fecal elimination accounts for about 25%, with the remainder as metabolites. |
| Half-life | Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 60 hours in severe impairment). |
| Protein binding | 98% bound to serum albumin. |
| Volume of Distribution | 0.15 L/kg, indicating limited extravascular distribution (primarily confined to plasma and interstitial fluid). |
| Bioavailability | Oral bioavailability: 45-55% (first-pass metabolism). Not applicable for intravenous route. |
| Onset of Action | Oral administration: 2-4 hours; intravenous: 5-15 minutes. |
| Duration of Action | Oral: 12-24 hours; intravenous: 6-12 hours. Clinical effects may persist beyond dosing interval due to prolonged half-life. |
| Molecular Weight | 315.4 |
300 mg orally twice daily, increased to 300 mg three times daily as tolerated. Maximum 900 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: 300 mg twice daily; GFR <30 mL/min or on hemodialysis: 300 mg once daily. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: 300 mg twice daily; Class C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Consider lower initial dose (300 mg twice daily) due to age-related renal impairment; monitor for cognitive effects. |
| 1st trimester | Insufficient human data; animal studies show risk. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Insufficient human data; potential fetal harm. Use only if clearly needed. |
| 3rd trimester | May cause neonatal toxicity; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for MERZEE (MERZEE).
| Placental transfer | Crosses placenta in animal studies; human data limited but likely. |
| Breastfeeding | Excreted in breast milk in low amounts, but potential for serious adverse reactions in nursing infants. Caution advised. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Insufficient human data; animal studies not available. Risk cannot be excluded. First trimester: potential for teratogenicity unknown; avoid if possible. Second and third trimesters: no specific risk identified but limited data. |
| Fetal Monitoring | Monitor maternal renal function, liver function, and blood counts throughout pregnancy. Fetal ultrasound for growth and anatomy if exposure occurs during first trimester. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility observed. |
■ FDA Black Box Warning
MERZEE has a high potential for abuse and dependence. Use in patients with a history of drug abuse or alcoholism is not recommended. Administration for extended periods may lead to drug dependence and must be avoided.
| Serious Effects |
Hypersensitivity to drug or any componentSevere hepatic impairment
| Precautions | Risk of abuse and dependence; monitor for signs of abuse. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or anxiety states. Discontinue if tolerance develops. May impair ability to drive or operate machinery. Do not use with MAOIs or within 14 days of their discontinuation. |
| Food/Dietary | High-fat meals reduce peak concentration (Cmax) by 28% and delay time to peak concentration (Tmax) by 2 hours. Grapefruit juice may increase perampanel levels via CYP3A4 inhibition; consider monitoring for side effects if consumed regularly. Alcohol and CNS depressants (e.g., benzodiazepines, opioids) may potentiate dizziness and sedation. |
| Clinical Pearls | MERZEE (perampanel) is a selective non-competitive AMPA receptor antagonist. Monitor for neuropsychiatric symptoms including hostility, aggression, and suicidal ideation, especially in patients with a history of psychiatric disorders. Due to its long half-life (~105 hours in steady state), dose adjustments should be made at intervals of at least 2 weeks. Avoid use in severe hepatic impairment (Child-Pugh C); dose reduction required for mild to moderate impairment. Contraception counseling is essential for women of childbearing potential as perampanel decreases efficacy of oral contraceptives containing levonorgestrel. Potent CYP3A4 inducers (e.g., carbamazepine, phenytoin) significantly reduce perampanel levels; consider dose adjustment. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly as this may increase seizure frequency. · May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects are known. · Report any changes in mood, behavior, or suicidal thoughts to your healthcare provider immediately. · Use effective non-hormonal contraception during treatment and for 1 month after stopping, as perampanel reduces efficacy of hormonal contraceptives. · Avoid alcohol and other CNS depressants as they can worsen side effects. · Do not take with high-fat meals as they delay absorption; take on an empty stomach or with a light meal. · Store at room temperature away from moisture and heat. |
Loading safety data…